Carebook Closes $2 million Convertible Debt Financing
MONTREAL, Dec. 11, 2023 /CNW/ - Carebook Technologies Inc. ("Carebook" or the "Company") (TSXV: CRBK) (OTCPK: CRBKF) (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, is pleased to announce the closing of its previously announced $2 million private placement of convertible debt (the "Transaction").
As previously announced, the Company entered into a convertible loan agreement (the "Loan Agreement") with UIL Limited, currently the Company's largest shareholder, (the "Lender") pursuant to which the Lender extended a loan in favour of the Company in the principal amount of $2 million.
The TSX Venture Exchange (the "Exchange") has conditionally approved the Transaction and the listing of the common shares of the Company (the "Common Shares") issuable upon the optional conversion of the principal amount under the Loan Agreement. The listing of the Common Shares issuable upon the optional conversion of the accrued but unpaid interest under the Loan Agreement will be subject to prior approval of the Exchange. The listing of the Common Shares issuable in connection with the automatic conversion of the principal amount and any accrued but unpaid interest thereon under the Loan Agreement, upon completion of an equity offering by the Company or other issuance of Common Shares having an aggregate fair market value of $2 million at the time of issuance (excluding for such purposes any Common Shares issued upon exercise or conversion of outstanding convertible securities of the Company) within six months of the closing of the Transaction, will also be subject to prior approval of the Exchange.
Disclosure Required under MI 61-101
The Lender is a "related party" of the Company within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). As a result, the Transaction is considered to be a "related party transaction" as such term is defined by MI 61-101, requiring the Company, in the absence of exemptions, to obtain a formal valuation of, and minority shareholder approval of, the "related party transaction". Pursuant to MI 61-101, the Company relied on an exemption from the formal valuation requirement as no securities of the Company are listed or quoted on certain specified exchanges, and on an exemption from the minority shareholder approval requirement as the fair market value of the convertible loans does not exceed $2.5 million, as determined in accordance with MI 61-101. Neither the Company nor, to the knowledge of the Company after reasonable inquiry, the Lender, has knowledge of any material information concerning the issuer or its securities that has not been generally disclosed. The Company intends to file a material change report within the required timeframe, which will contain all prescribed disclosure relating to this related party transaction.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined under applicable securities laws) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.
Information on the Lenders
UIL Limited ("UIL") is a London Stock Exchange listed investment company of which Mr. Alasdair Younie, a director of the Company, is a representative. Immediately prior to completion of the Transaction, UIL beneficially owned or exercised control or direction over, directly or indirectly, 61,046,167 Common Shares of the Company, representing 59.4% of the issued and outstanding Common Shares. UIL also owned, or had direction or control over, 568,383 warrants to purchase one Common Share and $2.25 million aggregate principal amount of loans convertible into up to 14,047,618 Common Shares.
Following completion of the Transaction, UIL beneficially owns or exercises control or direction over, directly or indirectly, 61,046,167 Common Shares, representing 59.4% of the issued and outstanding Common Shares, as well as 568,383 Common Share purchase warrants and $4.25 million aggregate principal amount of loans convertible into up to 34,047,618 Common Shares. Assuming a full conversion of the convertible loans under which UIL is a lender, and assuming the exercise in full of the warrants held by UIL, UIL would own, or have direction or control over, 95,622,168 Common Shares, representing in the aggregate approximately 69.6% of the issued and outstanding Common Shares (on a partially diluted basis).
The Loan Agreement described herein has been entered into by UIL for investment purposes. UIL may, from time to time, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over Common Shares or other securities of Carebook through market transactions, private agreements, or otherwise.
In accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, UIL will file an early warning report regarding this Transaction on the System for Electronic Document Analysis and Review + (SEDAR+) at www.sedarplus.ca under Carebook's issuer profile.
Carebook's digital health platform empowers its clients and more than 3.5 million members to take control of their health journey. During 2021, the Company completed the acquisitions of InfoTech Inc., a global leader in health and productivity risk management, and CoreHealth Technologies Inc., owner of an industry-leading wellness platform. In combination, these companies create a comprehensive digital health platform that includes both assessment tools and the technology to deliver complementary solutions. Carebook's shares trade on the Exchange under the symbol "CRBK," on the OTC Markets under the symbol "CRBKF," and are listed on the Open Market of the Frankfurt Stock Exchange under the symbol "PMM1." Carebook's head office is located at 1400-2045 Stanley Street, Montreal, Quebec H3A 2V4.
For further information contact:
Carebook Investor Relations Contact:
Olivier Giner, CFO
Email: [email protected]
Telephone: (450) 977-0709
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding forward-looking statements:
This release includes forward-looking information and forward-looking statements within the meaning of Canadian securities laws regarding Carebook, its subsidiaries and their business. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements are based on the current expectations of the management of Carebook and are based on assumptions and subject to risks and uncertainties. Although the management of Carebook believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and undue reliance should not be placed on such forward-looking statements. The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including the Company's inability to obtain listing approvals from the Exchange, economic factors, management's ability to manage and to operate the business of Carebook, management's ability to identify attractive M&A opportunities, management's ability to successfully integrate the Company's completed acquisitions and to realize the synergies of such acquisitions, management's ability to successfully complete product studies, the equity markets generally and risks associated with growth and competition, management's ability to achieve profitability for the Company, as well as the risk factors identified in the Company's management's discussion and analysis for the year ended December 31, 2022, a copy of which can be found on SEDAR+ under the Company's profile at www.sedarplus.ca. Although Carebook has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Carebook does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Carebook Technologies Inc.
Share this article